{"name":"Sumitomo Pharma (Suzhou) Co., Ltd.","slug":"sumitomo-pharma-suzhou-co-ltd","ticker":"","exchange":"","domain":"","description":"Sumitomo Pharma Company Limited  is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas. Its headquarters are located in Chuo-ku, Osaka.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Risperidone tablets","genericName":"Risperidone tablets","slug":"risperidone-tablets","indication":"Schizophrenia","status":"marketed"},{"name":"Lurasidone tablets","genericName":"Lurasidone tablets","slug":"lurasidone-tablets","indication":"Schizophrenia","status":"phase_3"},{"name":"Usual dose treatment of Tandospirone","genericName":"Usual dose treatment of Tandospirone","slug":"usual-dose-treatment-of-tandospirone","indication":"Generalized anxiety disorder","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Arotinolol Hydrochloride","genericName":"Arotinolol Hydrochloride","slug":"arotinolol-hydrochloride","indication":"Hypertension","status":"marketed"},{"name":"Non arotinolol group","genericName":"Non arotinolol group","slug":"non-arotinolol-group","indication":"Hypertension","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Etoposide-Cisplatin combined chemotherapy","genericName":"Etoposide-Cisplatin combined chemotherapy","slug":"etoposide-cisplatin-combined-chemotherapy","indication":"Small cell lung cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Metoprolol succinate sustained-release tablet","genericName":"Metoprolol succinate sustained-release tablet","slug":"metoprolol-succinate-sustained-release-tablet","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Risperidone tablets","genericName":"Risperidone tablets","slug":"risperidone-tablets","phase":"marketed","mechanism":"Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia","Bipolar disorder (acute mania and maintenance)","Irritability associated with autism spectrum disorder","Behavioral disturbances in dementia"],"catalyst":""},{"name":"Arotinolol Hydrochloride","genericName":"Arotinolol Hydrochloride","slug":"arotinolol-hydrochloride","phase":"marketed","mechanism":"Arotinolol hydrochloride is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate and blood pressure.","indications":["Hypertension","Angina pectoris"],"catalyst":""},{"name":"Etoposide-Cisplatin combined chemotherapy","genericName":"Etoposide-Cisplatin combined chemotherapy","slug":"etoposide-cisplatin-combined-chemotherapy","phase":"phase_3","mechanism":"Etoposide and cisplatin work together as a combination chemotherapy regimen that kills cancer cells by damaging DNA through different mechanisms.","indications":["Small cell lung cancer","Other solid tumors (specific indications in Phase 3 trial unknown)"],"catalyst":""},{"name":"Lurasidone tablets","genericName":"Lurasidone tablets","slug":"lurasidone-tablets","phase":"phase_3","mechanism":"Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors in the brain.","indications":["Schizophrenia","Bipolar I disorder depression","Major depressive disorder (adjunctive treatment)"],"catalyst":""},{"name":"Metoprolol succinate sustained-release tablet","genericName":"Metoprolol succinate sustained-release tablet","slug":"metoprolol-succinate-sustained-release-tablet","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Non arotinolol group","genericName":"Non arotinolol group","slug":"non-arotinolol-group","phase":"marketed","mechanism":"Non-arotinolol group refers to beta-blockers that are structurally distinct from arotinolol, used primarily for cardiovascular conditions.","indications":["Hypertension","Angina pectoris","Cardiac arrhythmias"],"catalyst":""},{"name":"Usual dose treatment of Tandospirone","genericName":"Usual dose treatment of Tandospirone","slug":"usual-dose-treatment-of-tandospirone","phase":"marketed","mechanism":"Tandospirone is a serotonin 1A (5-HT1A) receptor agonist that enhances serotonergic neurotransmission in the central nervous system.","indications":["Generalized anxiety disorder","Major depressive disorder"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"pipeline","source":"GlobeNewswire","summary":"Pharmaceutical and Biotechnology Royalty Rates Agreements - GlobeNewswire","headline":"Pharmaceutical and Biotechnology Royalty Rates Agreements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxQV3p0WXY5ZXdmOG1nQ0hYMFQyVWs2SDhvWjZYNm1XOGRBLXNPdzEtWGo5WTJvSVVRVi1icS05U1hQcUhGRGxGQWxxdF9qejJuWm1BYlRJT2dYaEVmTzkyclRQWllNSmVMSEZheW9TREtoQ05vTzUxQkdSSXE2UFFJOXNHSkNIU0RhU0szNVVTX1FIRU4zU1RLeWh6Q2d1LVZqRmIxNlJUZWFvSWplYWlWTjJoTW5DdnFYXy1Zc01QQzNiZmxSWVRjWU1ZQnFieE1sbDFwZG9JVGhOOVhZelpWM0ZMMXluU2VrdDBEVDliV0RyRmhZblVDREpvVkRhWGdhZTROUWZFaVlhM3FOWWJuRDZXemRkd21Tc2RDOEsxR3BHcW1saEItV1ZvUkxDendudDZBZHFwUlNCRzc2NVBCYmdrMzc?oc=5","date":"2025-08-28","type":"trial","source":"GlobeNewswire","summary":"Antisense Oligonucleotide Therapeutics Clinical Trial - GlobeNewswire","headline":"Antisense Oligonucleotide Therapeutics Clinical Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE5EMHJTYkZMb1Y2VjhkLTRWOTJCYmdHNHB3MVZsb05RSnhoN05KdkdUenpjXzVhelVaazN1M0xHNUwzaVNPcWZuX2VMYWNoTlhOd21jRHRBNDZDNXUxTlFGVm9yVnRpTEU?oc=5","date":"2025-08-19","type":"pipeline","source":"marubeni.com","summary":"Expansion of the Pharmaceutical Business in Africa: Growing the Scope of Marubeni's Pharmaceutical Strategic Platform - marubeni.com","headline":"Expansion of the Pharmaceutical Business in Africa: Growing the Scope of Marubeni's Pharmaceutical Strategic Platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxPN202TUJ4Nm1xZ3AwUEFZbjh0cGl1NWc5WDJFLW03VHhlZnV0R28wOFR4UC0wNlJnSHV6WVY4aG9mdEtDZ1phbHdKWnUyaEhuTzUteERfdkpJdnA1S1VZVGp3TlpwcXhxeEJZeEttTzYwZlNKTHBtZ0dXVGhtSnZZeUs3bkxhTFpVZ2d0c3d5Mm83eGtlRmZJU3FseW5lYVhoeVBESV8zRW9fb1FPTk1jd1ZUb1dyeGlrTFBuMUhCcFBzTnI2azJadG9fWHlxVS1RX0Roc3NNbnIwS19aVEJXbE5zQUJBUHVwdDhhYlluVGZhcXlRVW1wak5xazJ2bFlNMmFzaV9oVENvOWRsTEJFdVRwc2Z3TURveTlIRkJRQXpLV3JWTldMRnBwZG1EdEJSVGdTVlhUVktvS3drSHFrTGFZUmhpcnpOUXl2cEN5OERFZVpE?oc=5","date":"2025-06-17","type":"trial","source":"GlobeNewswire","summary":"Oligonucleotides Clinical Trial Pipeline Analysis - GlobeNewswire","headline":"Oligonucleotides Clinical Trial Pipeline Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPUHhxaGFRWDg0OGxIcXBWWlZreTFab01VRDhtSF9XVjdiQjZhcG5oYWttTmt2bVBvM3VFNWJzalMyWlc0Wms0a0lzX2l3Mm5YcExCN0hLWkktd1ZPcnF3UFNyUDZURksxeHp6eTRCUjc0V1BXTW9HZERUU09IYmZ0RUFtYTNVWDZkWUFsYVplOWFXbHE3R2xpUk9FN0Y1eXBGYUZkZU5pX2xsUTBOQVpDc21GSTNJS2ZIa3JkU0ktRlI4SUZuU1RTQWFNNlJ2bzA2UnBPQkZRaEhIR3FXN2tpUHIzN0xfSEZ5SUowNmVKZXZ4LVFsZmRj?oc=5","date":"2025-02-26","type":"pipeline","source":"PR Newswire","summary":"The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight - PR Newswire","headline":"The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxORnViXzB3VVFUSjAxaVdiMDNFS2d3b1BJallZZS1LVTBrU3NDampweURKeGVtaE9oS2FPc0M0MXpYdDdRSE8tTHNCZlVFSEk1RTdrU1Qxd3p4eGMxNXlpVWlHUTlrNjV5RkJHdjhWajVnSGxzcm9wV0JkMWtBVXZwQ29qcGZlVVdIcURDdm9MbEFuZ3lENTFua2dRQlUydTZjMnVFS2FXS2I0OUpSU2R0UzBnWmZaVlZza1lnSU5YMm5vU2dBeW81bGN4cW9UY1QtdkNCMWxqMUF5WHZGWVYydDc5RWhHWUFSV0FNZTNPOFgxdw?oc=5","date":"2025-02-20","type":"regulatory","source":"GlobeNewswire","summary":"BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire","headline":"BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNaXMtVzNSd1JKQ3JjZFBMQWxyd1RZME5iYWZ6c05QdDdQZ09abEZsUjdBb2U2XzYyb1FTY3dWOXRMTmRUSnZnTVQ2SmE4UFZpQWY3aVpBdm1hQTVTcER6c1k0M2lKSU5tTUFyU1dtQ1RwNGhBTTF4Q1NhOGlldk54MUlDN0E?oc=5","date":"2024-12-31","type":"pipeline","source":"BioSpace","summary":"Layoffs Continued Across Biopharma in 2024 - BioSpace","headline":"Layoffs Continued Across Biopharma in 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOalJtR2w0aVlVUFlGNlo5bEhmT1RxTmRmcm1FV1l0Z0dCQkVrSVN2aWo3dE1ERTBkR00zbzEwWUtGcjFiM2ZTc3NXeHBsbWZEYlU1Qk9QVXpvT21TMy10NlFiWnhXaTh5NXljeVJvalBmMkNBQXpfZzFUWHNJak1FLXlLZHptaGF2M2plZXQ3NjV3cjZLbmVhM3o1Q01CbXRiZFZQTm83Qlcyam93RnBJOFV4ZG9RU3cwZnJZTUhLejdNakZGbFZN?oc=5","date":"2024-10-01","type":"pipeline","source":"PR Newswire","summary":"PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight - PR Newswire","headline":"PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxOXzBuc0JZbVVfbkRlejRfMGJkSUd2dlRFVjk5VTRJNWNudzJqdWxWU3dKOUlSV19aTW1RSGZMZUtMTXp1VXZiSWtiRkxKS2xJdXNoOEJYXzNNMXZ4U0hQNGlFUE5GLXNZNXhGdUZjUkVHSlBfeTc5SlVzbnVhckh4WHhBV2VfNnN6bGZVYmx5a2RXd3p3OE81a3JzemttT1F1T190eTVkemg1V2p4NEI1cExteHY4ZnR6SE9kNEhPX2lGYTNURFp6eTZ3cG5UMGE4ekNHbHlnMV9icXB4Sk1RYVdIX0pHSy1sem5CLTBMVnN1WDA?oc=5","date":"2024-09-17","type":"trial","source":"PR Newswire","summary":"CEACAM5 Drugs Market Outlook: Rising Cancer Cases and Clinical Trials to Fuel Growth by 2034 | DelveInsight - PR Newswire","headline":"CEACAM5 Drugs Market Outlook: Rising Cancer Cases and Clinical Trials to Fuel Growth by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxORmREbWNJelp6ZXlnLXdmRHoxSTZtMThKUjE2b01fV2NOR05ZdWhJcENIOEtDakZLOTNJS0sxRVpyZDN3eEg4bzgtNzVlTjloeEhOcE82aE84WmMwME5lYXktZXNHSlJseTQteTFGVmRaMFNqbmx1T2hQcFNIMDhHbnhTek9kZWh6NFVWb2RLeUY4RUhwV0VZd3NmLW5rdWZkZUplZUR0UkF1ODVIVW9IM2NuS05qSEFUV0p1bHpjNkN6UVdCSnlqV0lhVGdKYVlmZHJUbW9aclVpLWVEVHFCSFZWSWQzdkQ4NjlKU29FOTVuXzA0d0RrbQ?oc=5","date":"2023-11-21","type":"trial","source":"PR Newswire","summary":"Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period (2019-2032) | DelveInsight - PR Newswire","headline":"Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period (2019-2032) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOSC1VYmZHakJ2cmdkTGg3cGh6Y0ZkTVVQUEluRzBONlV6ZTZwWXY2Y3ZKNUJ4Mi1zaUs5a053R1VKVVdjenZ3RzVUV05IZnNaWjBOcEY2eEhCckt3RHFlblBZT3NtcEZxWTNWNE52QVlSeWxORWhfWVNiTEp0U3RQUnFWcW9hcUt3TEZtWWdYS2FyVTNnampKaTJOLXBrZFRHb3hySmZxWmJESWM?oc=5","date":"2023-11-13","type":"pipeline","source":"Bloomberg.com","summary":"Race for First Drug Discovered by AI Nears Key Milestone - Bloomberg.com","headline":"Race for First Drug Discovered by AI Nears Key Milestone","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxNZHVkZFRxdnFCWHRsT1pkQWJieEItSXN2cHp2T0kzSEszMTdJa3JBVkFqMWFjZjJUR3dycWU1b24xM0htUmpRQXRvT01pQm5aaWtRM2tCMTN6RHVtaGpVdnVpc0pNUVJ0RmRGNHF3a2huUzBRSWRzT3ZHZ1oxdjlZVFkyUGZzNmlXQlN2OVJVV3IzTmg0UmFZaXZwMkJWSjcxa2x6WHlaaFpfNzRtWFdOQW9YNjZJbjlveEN1bk1jRHo0cTFkbTdpUkd6bzlLQ2xDMFUzcEpQcERqWmxxRDhYeFp5dEFLUXNELXlsQm82MXZrOTZvQzZtS19R?oc=5","date":"2021-10-06","type":"trial","source":"GlobeNewswire","summary":"Metastatic Colorectal Cancer Pipeline Review | Clinical Trials Analysis Report 2021 | DelveInsight - GlobeNewswire","headline":"Metastatic Colorectal Cancer Pipeline Review | Clinical Trials Analysis Report 2021 | DelveInsight","sentiment":"positive"}],"patents":[],"drugCount":7,"phaseCounts":{"marketed":5,"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}